

Haluk Ã-zen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11826122/publications.pdf>

Version: 2024-02-01

72
papers

1,795
citations

236925

25
h-index

276875

41
g-index

73
all docs

73
docs citations

73
times ranked

2203
citing authors

#	ARTICLE	IF	CITATIONS
1	Re: Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-specific Mortality Results from the International Staging Collaboration for Cancer of the Prostate. <i>European Urology</i> , 2022, , .	1.9	0
2	Predictors of ISUP score upgrade in patients with low-risk prostate cancer. <i>Tumori</i> , 2021, 107, 030089162094395.	1.1	2
3	Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 368.e19-368.e29.	1.6	3
4	How accurate is radiological imaging for perirenal fat and renal vein invasion in renal cell carcinoma?. <i>International Journal of Clinical Practice</i> , 2021, 75, e14359.	1.7	3
5	The effect of risk factors on surgical and oncological results in high-risk prostate cancer: A multicentre study of the urooncology society, Turkey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14281.	1.7	1
6	Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey. <i>Urologia Internationalis</i> , 2021, , 1-9.	1.3	0
7	Correlation of Prostate-Imaging Reporting and Data Scoring System scoring on multiparametric prostate magnetic resonance imaging with histopathological factors in radical prostatectomy material in Turkish prostate cancer patients: a multicenter study of the Urooncology Association. <i>Prostate International</i> . 2020. 8. 10-15.	2.3	17
8	Factors Affecting Surgical Margin Positivity after Radical Prostatectomy in the Turkish Population: A Multicenter Study of the Urooncology Association. <i>Urologia Internationalis</i> , 2020, 104, 724-730.	1.3	5
9	⁶⁸ Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 813-821.	2.2	15
10	Re: Active Surveillance in Younger Men with Prostate Cancer. <i>European Urology</i> , 2018, 73, 807.	1.9	0
11	Pathologic Outcomes of Candidates for Active Surveillance Undergoing Radical Prostatectomy: Results from a Contemporary Turkish Patient Cohort. <i>Urologia Internationalis</i> , 2018, 100, 43-49.	1.3	5
12	Pathological determinants of oncologic outcomes in stage II renal cell carcinoma: An international multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 535-535.	1.6	0
13	Predictors of Prostate Cancer in Ultrasound-Guided Transperineal Saturation Biopsy in Turkish Men with Multiple Prior Negative Biopsies. <i>Urologia</i> , 2016, 83, 71-76.	0.7	3
14	The nomogram conundrum: a demonstration of why a prostate cancer risk model in Turkish men underestimates prostate cancer risk in the USA. <i>International Urology and Nephrology</i> , 2016, 48, 1623-1629.	1.4	1
15	Microcontact imprinting based surface plasmon resonance (SPR) biosensor for real-time and ultrasensitive detection of prostate specific antigen (PSA) from clinical samples. <i>Sensors and Actuators B: Chemical</i> , 2016, 224, 823-832.	7.8	170
16	Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme. <i>European Journal of Cancer</i> , 2014, 50, 1090-1099.	2.8	88
17	Temporal changes in the survival of metastatic renal cell cancer patients and the impact of targeted agents: Single center experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 519-519.	1.6	2
18	Upper Urinary Tract Transitional Cell Carcinoma: Is There a Best?. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 39-44.	1.9	6

#	ARTICLE	IF	CITATIONS
19	Twenty Years and Counting: Is PSA Still Useful in 2010?. , 2012, , 13-24.		0
20	Presence of teratoma in orchiectomy specimen increases the need for postchemotherapy RPLND. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 38-42.	1.6	2
21	Retroperitoneal Lymph Node Dissection for the Primary Treatment Recommendation in Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Contrary to European Guidelines. European Urology Supplements, 2011, 10, e75-e80.	0.1	2
22	Is Prophylactic Breast Radiotherapy Necessary in All Patients With Prostate Cancer and Gynecomastia and/or Breast Pain?. Journal of Urology, 2010, 184, 519-524.	0.4	19
23	Renal cell carcinoma with inferior vena cava thrombus: The Hacettepe experience. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 603-609.	1.6	9
24	Incidental Diagnosis of Transitional Cell Carcinoma during Percutaneous Nephrolithotomy. Urologia Internationalis, 2009, 83, 291-294.	1.3	3
25	Radical Prostatectomy After Previous Prostate Surgery: Effects on Surgical Difficulty and Pathologic Outcomes. Urology, 2009, 73, 856-859.	1.0	18
26	Validation of Two Preoperative Kattan Nomograms Predicting Recurrence After Radical Prostatectomy for Localized Prostate Cancer in Turkey: A Multicenter Study of the Uro-oncology Society. Urology, 2009, 74, 1289-1295.	1.0	10
27	A New Device for the Treatment of Post-Prostatectomy Incontinence: Adjustable Perineal Male Sling. Journal of Urology, 2008, 179, 605-609.	0.4	13
28	Hormonal Predictors of Prostate Cancer. Urologia Internationalis, 2007, 79, 13-18.	1.3	44
29	Does Age Affect the Prognosis of Patients with Testicular Germ Cell Tumor?. Urologia Internationalis, 2007, 79, 117-123.	1.3	7
30	Correlation of Serum Androgens and Pituitary Hormone Levels with Serum PSA Less Than 2.5 NG/ML. Scientific World Journal, The, 2007, 7, 1128-1133.	2.1	3
31	The Effect of Prior Biopsy Scheme on Prostate Cancer Detection for Repeat Biopsy Population: Results of the 14-core Prostate Biopsy Technique. International Urology and Nephrology, 2007, 39, 189-195.	1.4	30
32	PSA Isoforms in Prostate Cancer Detection. European Urology Supplements, 2006, 5, 495-499.	0.1	29
33	Prognostic Significance of Bladder Tumor History and Tumor Location in Upper Tract Transitional Cell Carcinoma. Journal of Urology, 2006, 176, 48-52.	0.4	111
34	Outcomes of Surveillance Protocol of Clinical Stage I Nonseminomatous Germ Cell Tumorsâ€”Is Shift to Risk Adapted Policy Justified?. Journal of Urology, 2006, 176, 1424-1430.	0.4	45
35	Serum ribonuclease activity in the diagnosis of prostate cancer in men with serum prostate-specific antigen levels between 2.5 and 20 ng/mL. Clinical Biochemistry, 2006, 39, 363-366.	1.9	3
36	Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki-67. BJU International, 2005, 95, 650-654.	2.5	32

#	ARTICLE	IF	CITATIONS
37	Validation of 2001 Partin Tables in Turkey: A Multicenter Study. <i>European Urology</i> , 2005, 47, 185-189.	1.9	20
38	Can We Obtain Better Specimens with an End-Cutting Prostatic Biopsy Device?. <i>European Urology</i> , 2005, 47, 297-301.	1.9	19
39	Complexed Prostate Specific Antigen Density is Better Than the Other PSA Derivatives for Detection of Prostate Cancer in Men with Total PSA between 2.5 and 20ng/ml: Results of a Prospective Multicenter Study. <i>European Urology</i> , 2005, 47, 302-307.	1.9	18
40	INDIVIDUALIZATION OF THE BIOPSY PROTOCOL ACCORDING TO THE PROSTATE GLAND VOLUME FOR PROSTATE CANCER DETECTION. <i>Journal of Urology</i> , 2005, 173, 1536-1540.	0.4	57
41	Resection of pulmonary metastases following chemotherapy for high stage testicular tumors. <i>International Journal of Urology</i> , 2004, 11, 634-639.	1.0	5
42	An Extended 10-Core Transrectal Ultrasonography Guided Prostate Biopsy Protocol Improves the Detection of Prostate Cancer. <i>European Urology</i> , 2004, 45, 444-449.	1.9	116
43	CYP1A1 and GSTM1 polymorphic genotypes in patients with prostate cancer in a Turkish population. <i>Cancer Genetics and Cytogenetics</i> , 2004, 154, 81-85.	1.0	38
44	The Predictive Value Of Purified Protein Derivative Results On Complications And Prognosis In Patients With Bladder Cancer Treated With Bacillus Calmette-Guerin. <i>Journal of Urology</i> , 2003, 169, 1702-1705.	0.4	36
45	The role of the pathologist in the evaluation of radical prostatectomy specimens. <i>Scandinavian Journal of Urology and Nephrology</i> , 2003, 37, 387-391.	1.4	26
46	Gynecomastia following Chemotherapy for Testicular Cancer. <i>Urologia Internationalis</i> , 2003, 70, 253-254.	1.3	4
47	Telomerase Activity in Diagnosis of Bladder Cancer*. <i>Scandinavian Journal of Urology and Nephrology</i> , 2003, 37, 205-209.	1.4	11
48	Bladder cancer. <i>Current Opinion in Oncology</i> , 2002, 14, 265-272.	2.4	31
49	Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. <i>American Journal of Surgery</i> , 2002, 183, 292-299.	1.8	86
50	FALSE-POSITIVE RESULTS OF THE NMP22 TEST DUE TO HEMATURIA. <i>Journal of Urology</i> , 2002, 167, 555-558.	0.4	55
51	Determination of Prognosis in Patients With Prostate Cancer Treated With Radical Prostatectomy: Prognostic Value of CD44v6 Score. <i>Journal of Urology</i> , 2002, 167, 2037-2041.	0.4	21
52	Resection of residual masses alone: an alternative in surgical therapy of metastatic testicular germ cell tumors after chemotherapy. <i>Urology</i> , 2001, 57, 323-327.	1.0	25
53	Combined Use of Prostate-Specific Antigen Derivatives Decreases the Number of Unnecessary Biopsies to Detect Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001, 24, 610-613.	1.3	16
54	p53 codon 72 polymorphism in bladder cancer – no evidence of association with increased risk or invasiveness. <i>Urological Research</i> , 2001, 29, 393-395.	1.5	28

#	ARTICLE	IF	CITATIONS
55	Daily variability of serum prostate-specific antigen in men over 50 years of age. <i>International Urology and Nephrology</i> , 2001, 33, 641-644.	1.4	8
56	Radical cystectomy versus alternative treatments for muscle-confined bladder cancer. <i>International Urology and Nephrology</i> , 2001, 33, 357-362.	1.4	5
57	Polymorphisms of glutathione S-transferase genes (GSTM1 , GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population. <i>Archives of Toxicology</i> , 2001, 75, 459-464.	4.2	69
58	Glutathione S-transferase M1 gene polymorphism in bladder cancer patients. <i>Cancer Genetics and Cytogenetics</i> , 2001, 125, 1-4.	1.0	26
59	Percutaneous Nephrostomy in the Management of Malignant Ureteral Obstruction Secondary to Bladder Cancer. <i>Journal of Endourology</i> , 2001, 15, 827-829.	2.1	25
60	Bladder cancer. <i>Current Opinion in Oncology</i> , 2000, 12, 255-259.	2.4	22
61	Adjuvant chemotherapy for non-organ confined disease after radical cystectomy. , 2000, 32, 59-62.		2
62	Marsupialization for Bilateral Pararenal Lymphatic Cysts. <i>Scandinavian Journal of Urology and Nephrology</i> , 2000, 34, 77-78.	1.4	2
63	A STUDY OF THE ETIOLOGY OF IDIOPATHIC CALCIUM UROLITHIASIS IN CHILDREN: HYPOCITRURIA IS THE MOST IMPORTANT RISK FACTOR. <i>Journal of Urology</i> , 2000, 164, 162-165.	0.4	103
64	Human papillomavirus associated with bladder carcinoma? Analysis by polymerase chain reaction. <i>International Journal of Urology</i> , 1999, 6, 184-186.	1.0	25
65	Skeletal Muscle Metastasis from Carcinoma of the Bladder. <i>Scandinavian Journal of Urology and Nephrology</i> , 1999, 33, 336-337.	1.4	11
66	Bladder cancer. <i>Current Opinion in Oncology</i> , 1999, 11, 207.	2.4	18
67	PSYCHOSOCIAL ADJUSTMENT AFTER TESTICULAR CANCER TREATMENT. <i>Journal of Urology</i> , 1998, 159, 1947-1950.	0.4	34
68	DETECTION OF BACILLUS CALMETTE-GUERIN IN THE BLOOD BY THE POLYMERASE CHAIN REACTION METHOD OF TREATED BLADDER CANCER PATIENTS. <i>Journal of Urology</i> , 1997, 158, 2109-2112.	0.4	23
69	Gynecomastia as a complication of chemotherapy for testicular germ cell tumors. <i>Urology</i> , 1996, 48, 944-946.	1.0	20
70	Clinical significance of serum ferritin in patients with renal cell carcinoma. <i>Urology</i> , 1995, 46, 494-498.	1.0	31
71	Detection of urinary interleukin-2, interleukin-2 receptor, and tumor necrosis factor levels in patients with superficial bladder tumors after intravesical BCG immunotherapy. <i>Urology</i> , 1994, 43, 187-190.	1.0	15
72	Serum Ferritin: A Tumor Marker For Renal Cell Carcinoma. <i>Journal of Urology</i> , 1991, 145, 1134-1137.	0.4	34